PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10338910

Humana CHF program cuts costs, admissions.

View original source ↗Export metadata ↓

Abstract

The Buffalo Grove, IL-based Cardiac Solutions congestive heart failure program reduced admissions by 57.5%, inpatient costs by 61.1%, hospital days by 58%, and emergency department visits by 48.9% in a two-year study of nearly 5,000 Humana patients. The program relies heavily on frequent nursing contact in person and by telephone with patients to make sure they comply with doctors' orders and know how to identify early warning signs. Nurse disease managers provide the sometimes missing link between established treatment guidelines and implementation on the patient level.

Explore related subjects

Disease ManagementHealth Maintenance OrganizationsHeart FailureHospitals, ProprietaryHumansIllinoisNurse-Patient RelationsPatient AdmissionPractice Guidelines as TopicQuality of LifeTelephoneUnited StatesUnited States Agency for Healthcare Research and QualityJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

1998. Humana CHF program cuts costs, admissions.. https://pubmed.ncbi.nlm.nih.gov/10338910/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Chronic inflammatory demyelinating polyradiculopathy (CIDP), considered an immune-mediated disease, is likely under-recognized and under-treated due to its heterogeneous presentation and the limitations of clinical, serologic, and electrophysiologic diagnostic criteria. Despite these limitations, early diagnosis and treatment is important in preventing irreversible axonal loss and improving functional recovery. Primary treatment modalities include intravenous immunoglobulin and plasmapheresis, for which there is randomized, double-blind, placebo-controlled evidence. In addition, despite less definitive published evidence of efficacy, corticosteroids are considered standard therapies because of their long history of use. Studies have failed to demonstrate a difference in efficacy among these three treatments; consequently, the choice is usually based on availability and side-effect profile. A number of chemotherapeutic and immunosuppressive agents have also shown to be effective in treating CIDP but significant evidence is lacking; therefore, these agents are primarily used in conjunction with other modalities. Regardless of the treatment choice, long-term therapy is required to maintain a response and prevent relapse.

Disease Management↗
PubMed2007

Advances in the management of chronic obstructive pulmonary disease.

Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death, seems to be increasing in worldwide prevalence, and carries with it a significant health and economic burden. Smoking cessation is the only available intervention proven to halt disease progression. The authors discuss the role of the newly approved agent, varenicline, in promotion of smoking cessation. The remainder of presently available therapies treat the symptoms of COPD, but do not impact progression of disease. As the understanding of the pathogenesis of COPD improves, new targets for therapies are emerging. Given the large number of potential targets and the results of recent studies, it seems unlikely that a single new agent will result in a cure. Rather, management of COPD should involve a multi-pronged approach including smoking cessation, bronchodilators, treatment of infection, and eventual targeting of inflammatory pathways and genetic predispositions. In this article, the authors discuss presently available therapies as well as agents under development.

Disease Management↗